Project/Area Number |
20592014
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Otorhinolaryngology
|
Research Institution | University of Yamanashi |
Principal Investigator |
MASUYAMA Keisuke University of Yamanashi, 大学院・医学工学総合研究部, 教授 (30181663)
|
Co-Investigator(Kenkyū-buntansha) |
CHIKAMATSU Ichiro 山梨大学, 医学部附属病院, 講師 (30301378)
|
Co-Investigator(Renkei-kenkyūsha) |
MATSUOKA Tomokazu 山梨大学, 大学院・医学工学総合研究部, 助教 (30313810)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 抗癌剤耐性分子 / 癌幹細胞 / 制御性T細胞 / 頭頸部癌 / タキサン系抗癌剤 / 免疫療法 / TRAG-3 / 免疫化学療法 |
Research Abstract |
We found that head and neck cancer stem cells appeared to be resistant to the treatment of anti-cancer drugs. We did not find any differences of TRAG-3 mRNA expressions between CD44+ and CD44- cells of head and neck cancer cell lines. In addition, CD44+ cells significantly suppressed T cell proliferation. As for cytokine production, IFN・was reduced, however, IL-10 was increased when co-cultured with CD44+ cells. Thus, immunosuppressive mechanisims other than TRAG-3 expression may have a role for anti-cancer drug resistance.
|